Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification

References

• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305.
   PubMed Web of Science ®Google Scholar
• Kuro-o M. A potential link between phosphate and aging--lessons from Klotho-deficient mice. Mech Ageing Dev. 2010;131:270–275.
   PubMed Web of Science ®Google Scholar
• Kidney Disease/Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:4–150.
   Web of Science ®Google Scholar
• Martinez-Castelao A, Gorriz JL, Segura-De La Morena J, et al. Consensus document for the detection and management of chronic kidney disease. Nefrologia. 2014;34:243–262.
   PubMed Web of Science ®Google Scholar
• Kidney Disease/Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009;76:S1–S130. (Suppl 117).
   Google Scholar
• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–2218.
   PubMed Web of Science ®Google Scholar
• Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. Jama. 2011;305:2432–2439.
   PubMed Web of Science ®Google Scholar
• London GM, Guérin AP, Verbeke FH, et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol. 2007;18:613–620.
   PubMed Web of Science ®Google Scholar
• Fernandez-Martin JL, Martinez-Camblor P, Dionisi MP, et al. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transpl. 2015;30:1542–1551.
   PubMed Web of Science ®Google Scholar
• Wheeler DC, London GM, Parfrey PS, et al. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. J Am Heart Assoc. 2014;3:e001363.
   PubMed Web of Science ®Google Scholar
• Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69:1945–1953.
   PubMed Web of Science ®Google Scholar
• Torregrosa J-V, Bover J, Cannata Andia J, et al. Spanish society of nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.). Nefrologia. 2011;31(Suppl 1):3–32.
   PubMed Web of Science ®Google Scholar
• Bover J, Evenepoel P, Ureña-Torres P, et al. Pro: cardiovascular calcifications are clinically relevant. Nephrol Dial Transpl. 2015;30:345–351.
   PubMed Web of Science ®Google Scholar
• Zoccali C, London G. Con: vascular calcification is a surrogate marker, but not the cause of ongoing vascular disease, and it is not a treatment target in chronic kidney disease. Nephrol Dial Transpl. 2015;30:352–357.
   PubMed Web of Science ®Google Scholar
• Yusuf AA, Howell BL, Powers CA, et al. Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare part D. Am J Kidney Dis. 2014;64:770–780.
   PubMed Web of Science ®Google Scholar
• Bellasi A, Kestenbaum B. Pro: should phosphate binders be used in chronic kidney disease stage 3-4? Nephrol Dial Transpl. 2015;31(2):184–188.
   PubMed Web of Science ®Google Scholar
• Kestenbaum B, Bellasi A. Con phosphate binders in chronic kidney disease. Nephrol Dial Transpl. 2015;31(2):189–194.
   PubMed Web of Science ®Google Scholar
• Martín de Francisco AL. Should we consider the cost-effectiveness analysis to apply the recommendations for phosphate-binders administration? Nefrol Publicación of La Soc Española Nefrol. 2008;28:129–134.
   PubMed Web of Science ®Google Scholar
• Taylor MJ, Elgazzar HA, Chaplin S, et al. An economic evaluation of sevelamer in patients new to dialysis. Curr Med Res Opin. 2008;24:601–608.
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Tomlinson J, Walsh L, et al. Emerging drugs for secondary hyperparathyroidism. Expert Opin Emerg Drugs. 2015;20:197–208.
   PubMed Web of Science ®Google Scholar
• Spasovski G. Advances in pharmacotherapy for hyperphosphatemia in renal disease. Expert Opin Pharmacother. 2015;16:2589–2599.
   PubMed Web of Science ®Google Scholar
• Rodríguez M, Rodríguez-Ortiz ME. Advances in pharmacotherapy for secondary hyperparathyroidism. Expert Opin Pharmacother. 2015;16:1703–1716.
   PubMed Web of Science ®Google Scholar
• Ritter CS, Slatopolsky E. Phosphate toxicity in CKD: the killer among us. Clin J Am Soc Nephrol. 2016. pii: CJN11901115. doi:10.2215/CJN.11901115 [Epub ahead of print].
   PubMedGoogle Scholar
• Llach F, Bover J. Renal osteodystrophies. In: Brenner BM, editor. The kidney. 6th ed. Philadelphia (PA): WB Saunders Company; 2000. p. 2013–2186.
   Google Scholar
• Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370–1378.
   PubMed Web of Science ®Google Scholar
• Cernaro V, Santoro D, Lucisano S, et al. The future of phosphate binders: a perspective on novel therapeutics. Expert Opin Investig Drugs. 2014;23:1459–1463.
   PubMed Web of Science ®Google Scholar
• Gorriz JL, Molina P, Cerveron MJ, et al. Vascular calcification in patients with nondialysis CKD over 3 years. Clin J Am Soc Nephrol. 2015;10:654–666.
   PubMed Web of Science ®Google Scholar
• Di Iorio B, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012;7:487–493.
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–252.
   PubMed Web of Science ®Google Scholar
• Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71:438–441.
   PubMed Web of Science ®Google Scholar
• Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72:1130–1137.
   PubMed Web of Science ®Google Scholar
• St Peter WL, Liu J, Weinhandl E, et al. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis. 2008;51:445–454.
   PubMed Web of Science ®Google Scholar
• Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382:1268–1277.
   PubMed Web of Science ®Google Scholar
• Jean G, Lataillade D, Genet L, et al. Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: results from the French ARNOS study. Hemodial Int. 2011;15:485–492.
   PubMed Web of Science ®Google Scholar
• Bover J, Dasilva I, Furlano M, et al. Clinical Uses of 1,25-dihydroxy-19-nor-vitamin D(2) (Paricalcitol). Curr Vasc Pharmacol. 2014;12:313–323.
   PubMed Web of Science ®Google Scholar
• Bover J, Ureña P, Ruiz-García C, et al. Clinical and practical use of calcimimetics in dialysis patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2015;11(1):161–174.
   PubMed Web of Science ®Google Scholar
• Chertow GM, Block GA, Correa-Rotter R, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367:2482–2494.
   PubMed Web of Science ®Google Scholar
• Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transpl. 2011;26:1327–1339.
   PubMed Web of Science ®Google Scholar
• Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349:446–456.
   PubMed Web of Science ®Google Scholar
• Goldsmith DJA, Covic A, Vervloet M, et al. Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrol Dial Transplantation. 2015;30(5):698–700.
   PubMed Web of Science ®Google Scholar
• Miller PD. Bone disease in CKD: a focus on osteoporosis diagnosis and management. Am J Kidney Dis. 2014;64:290–304.
   PubMed Web of Science ®Google Scholar
• Betriu A, Martinez-Alonso M, Arcidiacono MV, et al. Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study. Nephrol Dial Transpl. 2014;29:1415–1422.
   PubMed Web of Science ®Google Scholar
• Martin M, Valls J, Betriu A, et al. Association of serum phosphorus with subclinical atherosclerosis in chronic kidney disease. Sex makes a difference. Atherosclerosis. 2015;241:264–270.
   PubMed Web of Science ®Google Scholar
• Gracia M, Betriu À, Martínez-Alonso M, et al. Predictors of subclinical atheromatosis progression over 2 years in patients with different stages of CKD. Clin J Am Soc Nephrol. 2015;11(2):287–296.
   PubMed Web of Science ®Google Scholar
• Ellam TJ, Chico TJA. Phosphate: the new cholesterol? The role of the phosphate axis in non-uremic vascular disease. Atherosclerosis. 2012;220:310–318.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Ruggenenti P, Perna A, et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol. 2011;22:1923–1930.
   PubMed Web of Science ®Google Scholar
• Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87:E10– E17.
   PubMed Web of Science ®Google Scholar
• Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16:520–528.
   PubMed Web of Science ®Google Scholar
• Foley RN, Collins AJ, Herzog CA, et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol. 2009;20:397–404.
   PubMed Web of Science ®Google Scholar
• Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393–4408.
   PubMed Web of Science ®Google Scholar
• Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584–592.
   PubMed Web of Science ®Google Scholar
• Scialla JJ, Wolf M. Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol. 2014;10:268–278.
   PubMed Web of Science ®Google Scholar
• Ketteler M, Elder GJ, Evenepoel P, et al. Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a kidney disease: improving global outcomes controversies conference. Kidney Int. 2015;87:502–528.
   PubMed Web of Science ®Google Scholar
• Selamet U, Tighiouart H, Sarnak MJ, et al. Relationship of dietary phosphate intake with risk of end-stage renal disease and mortality in chronic kidney disease stages 3-5: the modification of diet in renal disease study. Kidney Int. 2015. doi:10.1038/ki.2015.284. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Vervloet MG. Dietary phosphorus restriction in predialysis chronic kidney disease: time for a cease-fire? Kidney Int. 2016;89:21–23.
   PubMed Web of Science ®Google Scholar
• Malindretos P, Cozzolino M. Phosphate binders, past - present - future. A critical appraisal. Expert Opin Pharmacother. 2016;17(3):297–300.
   PubMed Web of Science ®Google Scholar
• Wu-Wong JR, Mizobuchi M. Is there a need for new phosphate binders to treat phosphate imbalance associated with chronic kidney disease? Expert Opin. Investig Drugs. 2014;23:1465–1475.
   Web of Science ®Google Scholar
• Shinaberger CS, Greenland S, Kopple JD, et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr. 2008;88:1511–1518.
   PubMed Web of Science ®Google Scholar
• Menon V, Kopple JD, Wang X, et al. Effect of a very low-protein diet on outcomes: long-term follow-up of the modification of diet in renal disease (MDRD) study. Am J Kidney Dis. 2009;53:208–217.
   PubMed Web of Science ®Google Scholar
• Uribarri J. Phosphorus additives in food and their effect in dialysis patients. Clin J Am Soc Nephrol. 2009;4:1290–1292.
   PubMed Web of Science ®Google Scholar
• Moe SM, Zidehsarai MP, Chambers MA, et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:257–264.
   PubMed Web of Science ®Google Scholar
• Noori N, Kalantar-Zadeh K, Kovesdy CP, et al. Association of dietary phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2010;5:683–692.
   PubMed Web of Science ®Google Scholar
• Mircescu G, Garneata L, Stancu SH, et al. Effects of a supplemented hypoproteic diet in chronic kidney disease. J Ren Nutr. 2007;17:179–188.
   PubMed Web of Science ®Google Scholar
• Cannata-Andia JB, Fernandez-Martin JL, Locatelli F, et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int. 2013;84:998–1008.
   PubMed Web of Science ®Google Scholar
• Lopes AA, Tong L, Thumma J, et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns sStudy (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis. 2012;60:90–101.
   PubMed Web of Science ®Google Scholar
• Isakova T, Gutierrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009;20:388–396.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation/Kidney Dialysis Outcome Quality Initiative. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1–S201.
   PubMedGoogle Scholar
• Zhai C-J, Yu X-S, Sun Q-L, et al. Effect of lanthanum carbonate versus calciumbased phosphate binders in dialysis patients: a meta-analysis. Clin Nephrol. 2014;82:372–378.
   PubMed Web of Science ®Google Scholar
• Ferreira A, Frazao JM, Monier-Faugere M-C, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008;19:405–412.
   PubMed Web of Science ®Google Scholar
• Bover J, Urena P, Brandenburg V, et al. Adynamic bone disease: from bone to vessels in chronic kidney disease. Semin Nephrol. 2014;34:626–640.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang Y, Chen H, et al. The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials. Ren Fail. 2014;36:1244–1252.
   PubMed Web of Science ®Google Scholar
• Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007;72:1255–1261.
   PubMed Web of Science ®Google Scholar
• Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–1483.
   PubMed Web of Science ®Google Scholar
• Toussaint ND, Lau KK, Polkinghorne KR, et al. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology (Carlton). 2011;16:290–298.
   PubMed Web of Science ®Google Scholar
• Wang C, Liu X, Zhou Y, et al. new conclusions regarding comparison of sevelamer and calcium-based phosphate binders in coronary-artery calcification for dialysis patients: a meta-analysis of randomized controlled trials. PLoS One. 2015;10:e0133938.
   PubMed Web of Science ®Google Scholar
• Barreto DV, Barreto F de C, de Carvalho AB, et al. Phosphate binder impact on bone remodeling and coronary calcification--results from the BRiC study. Nephron Clin Pract. 2008;110:c273–83.
   PubMed Web of Science ®Google Scholar
• Di Iorio B, Molony D, Bell C, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis. 2013;62:771–778.
   PubMed Web of Science ®Google Scholar
• Patel L, Bernard LM, Elder GJ. Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol. 2015;11(2):232–244.
   PubMed Web of Science ®Google Scholar
• Hill KM, Martin BR, Wastney ME, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int. 2013;83:959–966.
   PubMed Web of Science ®Google Scholar
• Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int. 2012;81:1116–1122.
   PubMed Web of Science ®Google Scholar
• Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012;23:1407–1415.
   PubMed Web of Science ®Google Scholar
• Seifert ME, de las Fuentes L, Rothstein M, et al. Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease. Am J Nephrol. 2013;38:158–167.
   PubMed Web of Science ®Google Scholar
• Massy ZA, Maizel J. [Pleiotropic effects of sevelamer: a model of intestinal tract chelating agent]. Nephrol Ther. 2014;10:441–450. France.
   PubMed Web of Science ®Google Scholar
• Isakova T, Ix JH, Sprague SM, et al. Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD. J Am Soc Nephrol. 2015;26:2328–2339.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A, et al. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transpl. 2011;26:2567–2571.
   PubMed Web of Science ®Google Scholar
• Urena-Torres P, Prie D, Keddad K, et al. Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial. BMC Nephrol. 2014;15:71.
   PubMed Web of Science ®Google Scholar
• Massy ZA, Drüeke TB. Magnesium and cardiovascular complications of chronic kidney disease. Nat Rev Nephrol. 2015;11:432–442.
   PubMed Web of Science ®Google Scholar
• Matias P, Azevedo A, Laranjinha I, et al. Lower serum magnesium is associated with cardiovascular risk factors and mortality in haemodialysis patients. Blood Purif. 2014;38:244–252.
   PubMed Web of Science ®Google Scholar
• Sakaguchi Y, Fujii N, Shoji T, et al. Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: a cohort study. PLoS One. 2014;9:e116273.
   Google Scholar
• Neven E, De Schutter TM, Dams G, et al. A magnesium based phosphate binder reduces vascular calcification without affecting bone in chronic renal failure rats. PLoS One. 2014;9:e107067.
   Google Scholar
• Spiegel DM, Farmer B. Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study. Hemodial Int. 2009;13:453–459.
   PubMed Web of Science ®Google Scholar
• Turgut F, Kanbay M, Metin MR, et al. Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol. 2008;40:1075–1082.
   PubMed Web of Science ®Google Scholar
• Tzanakis IP, Stamataki EE, Papadaki AN, et al. Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study. Int Urol Nephrol. 2014;46:2199–2205.
   PubMed Web of Science ®Google Scholar
• De Francisco ALM, Leidig M, Covic AC, et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transpl. 2010;25:3707–3717.
   PubMed Web of Science ®Google Scholar
• Covic A, Passlick-Deetjen J, Kroczak M, et al. A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol Dial Transpl. 2013;28:2383–2392.
   PubMed Web of Science ®Google Scholar
• Isakova T, Gutierrez OM, Smith K, et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transpl. 2011;26:584–591.
   PubMed Web of Science ®Google Scholar
• Lloret MJ, Ruiz-Garcia C, Dasilva I, et al. Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation - safety, efficacy, and patient adherence. Patient Prefer Adherence. 2013;7:1147–1156.
   PubMed Web of Science ®Google Scholar
• Dolores Arenas M, Perez-Garcia R, Bennouna M, et al. Improvement of therapeutic compliance in haemodialysis patients with poor phosphorus control and adherence to treatment with binders: COMQUELFOS study. Nefrologia. 2013;33:196–203.
   PubMed Web of Science ®Google Scholar
• Arenas MD, Malek T, Álvarez-Ude F, et al. [Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control]. Nefrol Publicación of La Soc Española Nefrol. 2010;30:522–530. Spanish
   PubMedGoogle Scholar
• Hutchison AJ. Novel phosphate binders: plus ça change, plus c’est la même chose. Kidney Int. 2014;86:471–474.
   PubMed Web of Science ®Google Scholar
• Burnier M, Pruijm M, Wuerzner G, et al. Drug adherence in chronic kidney diseases and dialysis. Nephrol Dial Transpl. 2015;30:39–44.
   PubMed Web of Science ®Google Scholar
• Delmez J, Block G, Robertson J, et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol. 2007;68:386–391.
   PubMed Web of Science ®Google Scholar
• Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol. 2008;3:1125–1130.
   PubMed Web of Science ®Google Scholar
• Tsukamoto Y. End-stage renal disease (ESRD) and its treatment in Japan. Nephrol Dial Transpl. 2008;23:2447–2450.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Spasovski G, Dimkovic N, et al. Long-term evaluation of colestilan in chronic kidney disease stage 5 dialysis patients with hyperphosphataemia. Blood Purif. 2015;41:247–253.
   PubMedGoogle Scholar
• Hertel J, Locatelli F, Spasovski G, et al. Randomized, double-blind, placebo-controlled, withdrawal study of colestilan after dose titration in chronic kidney disease dialysis patients with hyperphosphatemia. Nephron. 2015;130:229–238.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Del Vecchio L, Violo L, et al. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles. Expert Opin Drug Saf. 2014;13:551–561.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Dimkovic N, Spasovski G. Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients. Expert Opin Pharmacother. 2014;15:1475–1488.
   PubMed Web of Science ®Google Scholar
• Savica V, Calo LA, Monardo P, et al. Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. J Am Soc Nephrol. 2009;20:639–644.
   PubMed Web of Science ®Google Scholar
• Block GA, Persky MS, Shamblin BM, et al. Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney disease. Nephron Clin Pract. 2013;123:93–101.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Tsuruta Y, Okada Y, et al. Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial. BMC Nephrol. 2014;15:98.
   PubMed Web of Science ®Google Scholar
• Zhai C-J, Yu X-S, Yang X-W, et al. Effects and safety of iron-based phosphate binders in dialysis patients: a systematic review and meta-analysis. Ren Fail. 2015;37:7–15.
   PubMed Web of Science ®Google Scholar
• Pai AB, Jang SM, Wegrzyn N. Iron-based phosphate binders - a new element in management of hyperphosphatemia. Expert Opin Drug Metab Toxicol. 2016;12:115–127.
   PubMed Web of Science ®Google Scholar
• Negri AL, Urena Torres PA. Iron-based phosphate binders: do they offer advantages over currently available phosphate binders? Clin Kidney J. 2015;8:161–167.
   PubMedGoogle Scholar
• Yokoyama K, Hirakata H, Akiba T, et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol. 2014;9:543–552.
   PubMed Web of Science ®Google Scholar
• Phan O, Maillard M, Malluche HH, et al. Effects of sucroferric oxyhydroxide compared to lanthanum carbonate and sevelamer carbonate on phosphate homeostasis and vascular calcifications in a rat model of chronic kidney failure. Biomed Res Int. 2015;2015:515606.
   PubMed Web of Science ®Google Scholar
• Wuthrich RP, Chonchol M, Covic A, et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol. 2013;8:280–289.
   PubMed Web of Science ®Google Scholar
• Floege J, Covic AC, Ketteler M, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86:638–647.
   PubMed Web of Science ®Google Scholar
• Floege J, Covic AC, Ketteler M, et al. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transpl. 2015;30:1037–1046.
   PubMed Web of Science ®Google Scholar
• Vervloet M, Marzell B, Stauss-Gabo, et al. Phosphate binding efficacy of contemporary P-binders. Nephrol Dial Transplant. 2015;30(suppl 3):Su0024, (Abstract).
   Google Scholar
• Sprague SM, Coic A, Ketteler M, et al. Analysis of CKD-MBD markers in a phase 3 study of PA21 and sevelamer in patients with hiperphosphatemia. J Am Soc Nephrol. 2013;24(SAPO558):755A. Abstract.
   Google Scholar
• Pierce D, Hossack S, Poole L, et al. The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. Nephrol Dial Transpl. 2011;26:1615–1621.
   PubMed Web of Science ®Google Scholar
• Chong E, Kalia V, Willsie S, et al. Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects. J Nephrol. 2014;27(6):659–666.
   PubMed Web of Science ®Google Scholar
• Weitzman SP, Ginsburg KC, Carlson HE. Colesevelam hydrochloride and lanthanum carbonate interfere with the absorption of levothyroxine. Thyroid. 2009;19:77–79.
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Akiba T, Fukagawa M, et al. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transpl. 2014;29:1053–1060.
   PubMed Web of Science ®Google Scholar
• Lewis JB, Sika M, Koury MJ, et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol. 2015;26:493–503.
   PubMed Web of Science ®Google Scholar
• Lee C-T, Wu I-W, Chiang -S-S, et al. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study. J Nephrol. 2015;28:105–113.
   PubMed Web of Science ®Google Scholar
• Umanath K, Jalal DI, Greco BA, et al. Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J Am Soc Nephrol. 2015;26:2578–2587.
   PubMed Web of Science ®Google Scholar
• Schoninger LMR, Dall’Oglio RC, Sandri S, et al. Chitosan iron(III) reduces phosphorus levels in alloxan diabetes-induced rats with signs of renal failure development. Basic Clin Pharmacol Toxicol. 2010;106:467–471.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Origasa H, Kameoka C, et al. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study. Ther Apher Dial. 2014;18(Suppl 2):24–32.
   PubMed Web of Science ®Google Scholar
• Ito K, Takeshima A, Shishido K, et al. Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms. Ther Apher Dial. 2014;18(Suppl 2):19–23.
   PubMed Web of Science ®Google Scholar
• Nakaki J, Yamaguchi S, Torii Y, et al. Effect of fatty acids on the phosphate binding of TRK-390, a novel, highly selective phosphate-binding polymer. Eur J Pharmacol. 2013;714:312–317.
   PubMed Web of Science ®Google Scholar
• Sabbagh Y, Schiavi SC. Role of NPT2b in health and chronic kidney disease. Curr Opin Nephrol Hypertens. 2014;23:377–384.
   PubMed Web of Science ®Google Scholar
• Giral H, Caldas Y, Sutherland E, et al. Regulation of rat intestinal Na-dependent phosphate transporters by dietary phosphate. Am J Physiol Renal Physiol. 2009;297:F1466F1475.
   Google Scholar
• Berns JS. Niacin and related compounds for treating hyperphosphatemia in dialysis patients. Semin Dial. 2008;21:203–205.
   PubMed Web of Science ®Google Scholar
• Schiavi SC, Tang W, Bracken C, et al. Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol. 2012;23:1691–1700.
   PubMed Web of Science ®Google Scholar
• Eto N, Miyata Y, Ohno H, et al. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transpl. 2005;20:1378–1384.
   PubMed Web of Science ®Google Scholar
• Cheng SC, Young DO, Huang Y, et al. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:1131–1138.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Tanaka A, Nakamura T, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int. 2004;65:1099–1104.
   PubMed Web of Science ®Google Scholar
• A single and multiple oral dose study and a treatment schedule-finding study in non-elderly, healthy subjects. [cited 2016 Mar 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT02500953
   Google Scholar
• Single and multiple dosing study in hemodialysis patients with hyperphosphatemia in Japan. [cited 2016 Mar 28]. Available from: https://clinicaltrials.gov/ct2/show NCT02510274/
   Google Scholar
• Labonte ED, Carreras CW, Leadbetter MR, et al. Gastrointestinal inhibition of sodium-hydrogen exchanger 3 reduces phosphorus absorption and protects against vascular calcification in CKD. J Am Soc Nephrol. 2015;26:1138–1149.
   PubMed Web of Science ®Google Scholar
• Block GA, Ix JH, Ketteler M, et al. Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation. Am J Kidney Dis. 2013;62:457–473.
   PubMed Web of Science ®Google Scholar
• Block GA, Persky MS, Ketteler M, et al. A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodial Int. 2009;13:360–362.
   PubMed Web of Science ®Google Scholar
• Zhang S, Gillihan R, He N, et al. Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease. Kidney Int. 2013;84:713–721.
   PubMed Web of Science ®Google Scholar
• Kuro-o M. Klotho in health and disease. Curr Opin Nephrol Hypertens. 2012;21:362–368.
   PubMed Web of Science ®Google Scholar
• Shalhoub V, Shatzen EM, Ward SC, et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest. 2012;122:2543–2553.
   PubMed Web of Science ®Google Scholar
• Wohrle S, Henninger C, Bonny O, et al. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013;28:899–911.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, et al. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis. 2005;46:68–77.
   PubMed Web of Science ®Google Scholar
• Bover J, Ureña P, Lloret MJ, et al. Integral pharmacological management of bone mineral disorders in chronic kidney disease (Part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification. Expert Op Pharmacother. 2016.
   Google Scholar